Vir Biotechnology, Inc. stock is up 18.56% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 PUTs. 100% of analysts rate it a buy.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs, for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health.